Compliance with Market Abuse Regulation

RNS Number : 4216W
Odyssean Investment Trust PLC
17 April 2023
 

Odyssean Investment Trust plc

(the "Company")

LEI: 213800RWVAQJKXYHSZ74

 

 

 

Compliance with Market Abuse Regulation

 

17 April 2023

 

The Company confirms that:

 

a)  all inside information which the Directors and Company may have had has been notified to a Regulated Information Service ("RIS");

 

b)  the Company's net asset value per share is calculated and announced through a RIS on a daily basis;

 

c)  the Company has no reason to believe that there will be any material difference between the net asset value per share as at close of business on Friday, 31 March 2023, which was announced on Monday, 3 April 2023, and the financial information to be published in the announcement of its results for the year ended 31 March 2023.

 

The Company is, therefore, not prohibited from dealing in its own securities during the closed period, as defined by the Market Abuse Regulation, which will end on the date of the publication of its results for the year ended 31 March 2023, expected to be on or around Tuesday, 30 May 2023. 

 

 

-ENDS-

For further information please contact:

Mark Pope 

Frostrow Capital LLP 

0203 008 4913

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CMCGPUQCCUPWURM
UK 100

Latest directors dealings